121 related articles for article (PubMed ID: 18849357)
1. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice.
Parlevliet ET; Schröder-van der Elst JP; Corssmit EP; Picha K; O'Neil K; Stojanovic-Susulic V; Ort T; Havekes LM; Romijn JA; Pijl H
J Pharmacol Exp Ther; 2009 Jan; 328(1):240-8. PubMed ID: 18849357
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet.
Parlevliet ET; de Leeuw van Weenen JE; Romijn JA; Pijl H
Am J Physiol Endocrinol Metab; 2010 Aug; 299(2):E318-24. PubMed ID: 20530733
[TBL] [Abstract][Full Text] [Related]
3. Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet.
Parlevliet ET; Heijboer AC; Schröder-van der Elst JP; Havekes LM; Romijn JA; Pijl H; Corssmit EP
Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E142-7. PubMed ID: 17971509
[TBL] [Abstract][Full Text] [Related]
4. High-fat- and lipid-induced insulin resistance in rats: the comparison of glucose metabolism, plasma resistin and adiponectin levels.
Li L; Yang G; Li Q; Tang Y; Li K
Ann Nutr Metab; 2006; 50(6):499-505. PubMed ID: 17191023
[TBL] [Abstract][Full Text] [Related]
5. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
Tomas E; Wood JA; Stanojevic V; Habener JF
Regul Pept; 2011 Aug; 169(1-3):43-8. PubMed ID: 21549160
[TBL] [Abstract][Full Text] [Related]
6. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.
Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Patel K; Bahekar R; Shah G; Jain M
Can J Physiol Pharmacol; 2013 Dec; 91(12):1009-15. PubMed ID: 24289070
[TBL] [Abstract][Full Text] [Related]
7. Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis.
Picha KM; Cunningham MR; Drucker DJ; Mathur A; Ort T; Scully M; Soderman A; Spinka-Doms T; Stojanovic-Susulic V; Thomas BA; O'Neil KT
Diabetes; 2008 Jul; 57(7):1926-34. PubMed ID: 18426860
[TBL] [Abstract][Full Text] [Related]
8. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites.
Lam TK; van de Werve G; Giacca A
Am J Physiol Endocrinol Metab; 2003 Feb; 284(2):E281-90. PubMed ID: 12531742
[TBL] [Abstract][Full Text] [Related]
9. Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice.
Burmeister MA; Ferre T; Ayala JE; King EM; Holt RM; Ayala JE
Am J Physiol Endocrinol Metab; 2012 Feb; 302(3):E334-43. PubMed ID: 22094469
[TBL] [Abstract][Full Text] [Related]
10. Hepatic glucose production is more sensitive to insulin-mediated inhibition than hepatic VLDL-triglyceride production.
den Boer MA; Voshol PJ; Kuipers F; Romijn JA; Havekes LM
Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1360-4. PubMed ID: 16849628
[TBL] [Abstract][Full Text] [Related]
11. Lipoproteins abnormalities in obese insulin-resistant dogs.
Bailhache E; Nguyen P; Krempf M; Siliart B; Magot T; Ouguerram K
Metabolism; 2003 May; 52(5):559-64. PubMed ID: 12759884
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus.
Annuzzi G; De Natale C; Iovine C; Patti L; Di Marino L; Coppola S; Del Prato S; Riccardi G; Rivellese AA
Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2397-402. PubMed ID: 15458975
[TBL] [Abstract][Full Text] [Related]
13. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis.
Boden G; Cheung P; Stein TP; Kresge K; Mozzoli M
Am J Physiol Endocrinol Metab; 2002 Jul; 283(1):E12-9. PubMed ID: 12067837
[TBL] [Abstract][Full Text] [Related]
14. Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance.
Zinker B; Mika A; Nguyen P; Wilcox D; Ohman L; von Geldern TW; Opgenorth T; Jacobson P
Metabolism; 2007 Mar; 56(3):380-7. PubMed ID: 17292727
[TBL] [Abstract][Full Text] [Related]
15. Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice.
van den Hoek AM; Heijboer AC; Voshol PJ; Havekes LM; Romijn JA; Corssmit EP; Pijl H
Am J Physiol Endocrinol Metab; 2007 Jan; 292(1):E238-45. PubMed ID: 16940471
[TBL] [Abstract][Full Text] [Related]
16. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice.
Ayala JE; Bracy DP; Julien BM; Rottman JN; Fueger PT; Wasserman DH
Diabetes; 2007 Apr; 56(4):1025-33. PubMed ID: 17229936
[TBL] [Abstract][Full Text] [Related]
17. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
[TBL] [Abstract][Full Text] [Related]
18. Regulation of muscle malonyl-CoA levels in the nutritionally insulin-resistant desert gerbil, Psammomys obesus.
Shafrir E; Ziv E; Saha AK; Ruderman NB
Diabetes Metab Res Rev; 2002; 18(3):217-23. PubMed ID: 12112940
[TBL] [Abstract][Full Text] [Related]
19. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet.
van den Hoek AM; Heijboer AC; Corssmit EP; Voshol PJ; Romijn JA; Havekes LM; Pijl H
Diabetes; 2004 Aug; 53(8):1949-52. PubMed ID: 15277371
[TBL] [Abstract][Full Text] [Related]
20. The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp.
Wu H; Sui C; Xu H; Xia F; Zhai H; Zhang H; Weng P; Han B; Du S; Lu Y
J Diabetes Res; 2014; 2014():524517. PubMed ID: 25580440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
